1. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC);Cohen;J Immunother Cancer,2019
2. Racial differences in nasopharyngeal carcinoma in the United States;Wang;Cancer Epidemiol,2013
3. Increasing incidence of Epstein-Barr virus-related nasopharyngeal carcinoma in the United States;Argirion;Cancer,2020
4. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Head and Neck Cancers Version 1.2022. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1437. Accessed April 4, 2022.
5. Ayodele O, Siu LL. New drugs for recurrent or metastatic nasopharyngeal cancer. In: Vermorken JB, Budach V, Leemans CR, Machiels JP, Nicolai P, O’Sullivan B, editors. Critical issues in head and neck oncology. 10.1007/978-3-030-63234-2_23.